The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease

IF 12.8 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2026-10-01 DOI:10.1002/alz.71819

Jack M. Chapel,Bryan Tysinger,Hossein Pourmand,Dana Goldman,Paul Aisen,for the Alzheimer's Disease Neuroimaging Initiative

{"title":"The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease","authors":"Jack M. Chapel,Bryan Tysinger,Hossein Pourmand,Dana Goldman,Paul Aisen,for the Alzheimer's Disease Neuroimaging Initiative","doi":"10.1002/alz.71819","DOIUrl":null,"url":null,"abstract":"Abstract INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression by 29% over individuals’ remaining lifetime (baseline mean age: 73.0); earlier treatment initiated 2 years earlier. RESULTS Treatment generated $104,885 (95% CI: $99,291, $110,479) in gross societal value over an individual's lifetime, including quality‐of‐life gains, reduced caregiving burden, and medical cost offsets driven by reduced nursing home use and Medicaid spending. Earlier treatment increased value 32%; this rose to 71% if treatment effects are also stronger (36% slowing) in earlier AD stages. Scenarios with 4‐year effect duration yielded $49,122 (treatment) and $56,385 (earlier treatment). DISCUSSION Timely treatment consistently increased long‐term societal value. The findings provide a benchmark against which treatment implementation costs can be weighed.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"13 1","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.71819","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression by 29% over individuals’ remaining lifetime (baseline mean age: 73.0); earlier treatment initiated 2 years earlier. RESULTS Treatment generated $104,885 (95% CI: $99,291, $110,479) in gross societal value over an individual's lifetime, including quality‐of‐life gains, reduced caregiving burden, and medical cost offsets driven by reduced nursing home use and Medicaid spending. Earlier treatment increased value 32%; this rose to 71% if treatment effects are also stronger (36% slowing) in earlier AD stages. Scenarios with 4‐year effect duration yielded $49,122 (treatment) and $56,385 (earlier treatment). DISCUSSION Timely treatment consistently increased long‐term societal value. The findings provide a benchmark against which treatment implementation costs can be weighed.

查看原文本刊更多论文

抗淀粉样蛋白及时治疗阿尔茨海默病的价值

抗淀粉样蛋白疗法可以减缓阿尔茨海默病（AD）的进展；诊断和治疗的延误可能会降低它们的价值。方法：使用动态微观模拟，我们估计抗淀粉样蛋白治疗对早期症状性阿尔茨海默病美国人的总社会价值。在个体的剩余生命中，治疗方案使临床进展率减慢了29%（基线平均年龄：73.0岁）；早在2年前就开始了治疗。结果：在个体的一生中，治疗产生了104,885美元（95% CI: 99,291美元，110,479美元）的总社会价值，包括生活质量的提高，护理负担的减轻，以及疗养院使用和医疗补助支出减少所带来的医疗成本抵消。早期治疗价值提高32%；如果在早期AD阶段治疗效果也更强（36%减缓），这一比例上升到71%。效果持续时间为4年的方案产生49,122美元（治疗）和56,385美元（早期治疗）。及时治疗持续增加长期社会价值。研究结果提供了衡量治疗实施成本的基准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.